AGARWALEYE500.20

Dr. Agarwal's Health Care Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersAKUMSADVENZYMESALIVUSAARTIPHARMAARTIDRUGSAPLLTDCORONAHCGMcap ₹15,846 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations430.7460.2487.4498.7529.9564.1614.0
Other Income12.715.413.47.910.512.66.4
Total Income443.4475.7500.8506.6540.4576.7620.4
Expenses
+ Cost of Materials Consumed0.40.30.20.20.20.20.3
+ Purchases of Stock-in-Trade40.744.249.245.150.357.864.5
+ Changes in Inventories-5.3-0.6-1.80.9-3.9-5.8-5.7
+ Employee Benefit Expense83.987.195.599.1105.4103.8121.0
+ Finance Costs28.425.024.722.621.122.123.4
+ Depreciation & Amortisation58.260.463.067.968.876.778.3
+ Other Expenses196.2198.2216.4217.2233.7246.6263.4
Total Expenses402.4414.6447.2453.0475.6501.4545.3
EBITDA114.8131.0127.9136.1144.1161.5170.4
EBIT56.670.664.968.375.484.892.1
Profit
PBT before Exceptional Items41.061.053.653.764.875.375.1
+ Exceptional Items0.0-2.50.00.00.01.30.0
Pretax Income41.058.553.653.764.876.675.1
+ Current Tax9.710.817.618.819.924.725.0
+ Deferred Tax3.15.2-2.0-1.61.21.9-4.8
Tax Expense12.816.015.517.221.126.720.1
Net Income28.242.638.136.543.650.055.0
+ Net Income — Continuing Ops28.242.638.136.543.650.055.0
+ Other Comprehensive Income1.42.76.93.91.85.02.4
Total Comprehensive Income29.745.344.940.445.455.057.4
Net Income to Common22.332.630.129.733.739.745.2
Minority Interest5.910.08.06.89.910.39.8
Per Share
Basic EPS0.731.040.950.941.071.251.43
Diluted EPS0.721.030.950.931.061.241.42
Other Comprehensive Income — detail
+ Other Comprehensive Income2.76.93.91.85.02.4
+ Items NOT to be Reclassified to P&L-0.61.2-0.1-0.0-0.90.3-1.6
+ Tax on Items NOT to be Reclassified0.3-0.00.0-0.20.1-0.4
+ Tax on Items NOT to be Reclassified — alt tag-0.1
+ Items to be Reclassified to P&L1.91.92.54.83.5
+ Tax on Items to be Reclassified0.0-7.0-3.90.00.00.0
Comprehensive Income — Owners of Parent1.535.236.833.635.744.747.7
Comprehensive Income — Non-controlling Interests-0.010.18.16.89.710.39.7
Per Share — as-filed variants
Basic EPS — Continuing Operations0.731.040.950.941.071.251.43
Diluted EPS — Continuing Operations0.721.030.950.931.061.241.42
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit394.9416.4439.8452.5483.2511.8554.9
Gross Margin %91.6990.4790.2390.7491.1990.7390.36
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)41.061.053.653.764.875.375.1
− Exceptional Items (reconciliation)0.0-2.50.00.00.01.30.0
Net Income Adj (tax-effected)28.244.438.136.543.649.155.0
EPS Adj0.731.080.950.941.071.231.43
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.001.001.001.00
Paid Up Equity Capital30.831.631.631.631.731.731.7
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.